Our findings suggest that postischemic treatment with KRS or KGS attenuates cerebral ischemia-reperfusion injury and neuroinflammation by inhibiting the activation of STAT3 and NF-κB and has the therapeutic potential for the neuroinflammation-related diseases, such as ischemic stroke. Here, STAT3 is linked to brain ischemia.